CIA
ARQT icon

Capital Impact Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Capital Impact Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,147
Closed -$606K – 7
2024
Q2 		$606K Buy
+65,147
New +$589K 1.71% 37

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Impact Advisors's ARQT Position: Q3 2024 in Review

Capital Impact Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 65,147 shares — an estimated $606K sold.

Capital Impact Advisors first reported a position in ARQT in Q2 2024 and held it in 1 quarter. The position peaked at $606K in Q2 2024. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

  • Capital Impact Advisors reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 65,147 Arcutis Biotherapeutics shares in Q3 2024, an estimated $606K.
  • Capital Impact Advisors first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 1 quarter.
  • Capital Impact Advisors's Arcutis Biotherapeutics position peaked at $606K in Q2 2024.
  • 188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Capital Impact Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.